Abstract 519: Identification of a novel target for antibody therapy of breast cancer

Abstract Identification of breast cancer-specific antigens may promote development of safe and successful immunotherapy of breast cancer. Caprin-1 has been known to be an intracellular protein related to cell proliferation as a function, but it has not been reported to be a target for the treatment...

Full description

Saved in:
Bibliographic Details
Published inCancer research (Chicago, Ill.) Vol. 72; no. 8_Supplement; p. 519
Main Authors Okano, Fumiyoshi, Saito, Takanori, Ido, Takayoshi, Kurihara, Akira, Kobayashi, Shinichi, Narita, Yoshinori, Minamida, Yoshitaka, Sato, Masahiro, Toriyama, Yuko, Yonehara, Tetsu
Format Journal Article
LanguageEnglish
Published 15.04.2012
Online AccessGet full text

Cover

Loading…
More Information
Summary:Abstract Identification of breast cancer-specific antigens may promote development of safe and successful immunotherapy of breast cancer. Caprin-1 has been known to be an intracellular protein related to cell proliferation as a function, but it has not been reported to be a target for the treatment of cancer. Here we report that this molecule is a novel breast cancer antigen which can be targeted for antibody therapy. Caprin-1 is highly expressed in at least 70% of breast cancers based on the results of immunohistochemical staining of human several breast cancer tissues, but hardly expressed in human normal tissues. Importantly, a part of this molecule is highly expressed in extracellular region of many breast cancer cells. A mouse monoclonal antibody raised against the extracellular domain of Caprin-1 showed anti-tumor effects in all tumor-bearing mouse models in which various cancer cells expressing Caprin-1 were implanted. The monoclonal antibody induced complete regression in one of the tumor-bearing models. Humanized antibody has been prepared and preclinical studies are currently underway. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 103rd Annual Meeting of the American Association for Cancer Research; 2012 Mar 31-Apr 4; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2012;72(8 Suppl):Abstract nr 519. doi:1538-7445.AM2012-519
ISSN:0008-5472
1538-7445
DOI:10.1158/1538-7445.AM2012-519